Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Completed · Phase 3 · Has a placebo group
Conditions studied: Idiopathic Pulmonary Fibrosis
In brief
The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.
Key facts
- Study ID
- NCT00287729
- Run by
- Genentech, Inc.
- People needed
- 344
- Starts
- 2006-04-01
- Expected to finish
- 2008-11-01
- Last updated by the study team
- 2017-04-17
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- InterMune, Inc. — Brisbane, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.